Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 82

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 82
---
, Sanofi entered into a Separation Agreement and certain other agreements with Opella on July 22, 2024 (to be amended on or around the date of the SPA) to effect the separation of the Opella business and provide a framework for their ongoing relationship. The Separation Agreement sets out the rights and obligations of the parties with respect to the separation, including the terms and conditions governing the transfer of assets to, and assumption of liabilities by, each of the Opella group and the Sanofi group. In particular, Sanofi has agreed to retain Gold Bond Co LLC and its business. The Sanofi group and the Opella group have each agreed, subject to certain exceptions, to release and indemnify the other party and each of their respective past, present and future directors, officers, managers, agents and employees and each of the heirs, executors, administrators, successors and assigns of any of the foregoing from any and all claims against any of them that arise out of or relate to their respective businesses.

| SANOFIFORM 20-F2024 | 33 |

| PART I                             |
| ITEM 4. Information on the Company |

The Sanofi group has agreed to indemnify the Opella group in respect of all liabilities relating to, arising out of or resulting from among other things, Sanofi’s retained businesses including environmental liabilities, whether arising before or after the Closing, and certain liabilities relating to (i) the commercialization of any Zantac branded products (i.e., products containing ranitidine as its active pharmaceutical ingredient) prior to Closing, including certain product liability claims, and (ii) all personal injury claims resulting from the manufacturing or handling of Zantac prior to Closing (see Note D.22.a to the consolidated financial statements included at Item 18. of this annual report). B.4. Global research & development The ambition of Sanofi Research & Development (R&D) is to develop first-in-class or best-in-class medicines that respond to the urgent needs of patients, leveraging our leadership in immunology across all other therapeutic areas. This ambition is reflected in our R&D pipeline, which is presented in “— B.4.1. Biopharma pipeline” below. Discovering and developing new medicines is a costly, lengthy, and uncertain process and our continuous investments in R&D for future products and for the launches of newly registered medicines could result in increased costs without a proportionate increase in revenues. See “Item 3. Key Information — D. Risk Factors” for further information